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aving It Both Ways*
ohn A. Bittl, MD,† David J. Maron, MD‡
cala, Florida; and Nashville, Tennessee
o fail-safe method can determine which patients with
cute coronary syndromes (ACS) will stabilize on medical
herapy alone or require early angiography and percutaneous
oronary intervention (PCI). Troponin elevation, one of the
trongest predictors of the presence of coronary artery
isease in risk models of ACS (1), frequently triggers an
mmediate invasive evaluation. But the effect of early an-
iography on late mortality has been mixed (1). As a result,
contrasting, but not totally exclusive approaches have
merged for the management of patients with ACS: a
outine early invasive strategy and a delayed selective inva-
ive strategy.
See page 858
In this issue of the Journal, Damman et al. (2) present the
-year follow-up of the ICTUS (Invasive versus Conserva-
ive Treatment in Unstable coronary Syndromes) trial. In
he original report (3), patients with non–ST-segment
levation myocardial infarction (NSTEMI) assigned to the
arly invasive strategy within 24 to 48 h were as likely as
hose randomized to conservative management to experi-
nce the primary outcome of death, myocardial infarction
MI), or rehospitalization for angina within 1 year (22.7%
s. 21.2%). All patients in the ICTUS study had an elevated
roponin T level, but the early invasive strategy did not
onfer a better outcome in the presence of additional
igh-risk features such as advanced age, ST-segment de-
ression, or a high level of troponin T (3). The 3-year
ollow-up study (4) also reported similar rates for the
ombined primary end point for both strategies (30.0% vs.
6.0%). Because of the possibility of late attrition in the
onservatively managed patients, the 5-year follow-up was
ompleted and reported here (2).
quipoise. The current report (2) describes similar 5-year
umulative event rates for the composite end point of death
r spontaneous MI for the routine invasive and selective
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Ocala Heart Institute, Munroe Regional Medical Center, Ocala,(
lorida; and the ‡Cardiovascular Division, Vanderbilt University Medical Center,
ashville, Tennessee.nvasive groups (17.5% vs. 16.1%). Trends for other end
oints were suggested, but no conclusive differences ap-
eared between the early versus selective invasive strategies
n the rates of spontaneous MI (8.6% vs. 9.4%), all-cause
ortality (11.1% vs. 9.9%), or cardiovascular death (6.5% vs.
.8%). Of note, no significant differences between the 2
pproaches emerged across a broad range of risk scores, and
here was no late-mortality effect (2).
Although the ICTUS study was originally designed to
ontrast 2 strategies that differed in the timing and use of
nvasive procedures (2), most patients in both groups had
ndergone angiography during the initial hospitalization,
uring which 76% in the early invasive group and 40% in
he selective invasive group had also required revasculariza-
ion (3). During the 5 years of observation, the majority of
atients in both groups ultimately underwent PCI or bypass
urgery (81% vs. 60%) (2).
rawbacks of the early invasive strategy. A greater num-
er of periprocedural MIs was the major limitation of the
arly invasive strategy in the ICTUS trial (3). The finding
as consistent across a range of definitions, which altered
he absolute, but not the relative, rates of ischemic events
etween the 2 strategies (3). An ascertainment bias against
he early invasive group may have emerged during follow-
p, however, because of the nonsystematic collection of data
or periprocedural MIs after 3 years (2).
New information about the prognostic implications of
eriprocedural MIs continues to appear in the contemporary
iterature. A recent study from the Mayo Clinic registry has
uggested that spontaneous pre-procedural troponin eleva-
ion independently predicted death over a median follow-up
f 28 months (hazard ratio [HR]: 1.8, 95% confidence
nterval [CI]: 1.4 to 2.4), but the occurrence of procedural-
elated myonecrosis did not (5). An analysis from the
CUITY (Acute Catheterization and Urgent Intervention
riage Strategy) trial has found that spontaneous MIs
nrelated to PCI were strong independent predictors of
-year mortality (HR: 7.5, 95% CI: 5.0 to 11.3), whereas
rocedure-related MIs were not (6). In the ICTUS trial, the
arly invasive approach resulted in more post-procedural
schemic events than the delayed selective strategy but was
ot associated with increased cardiovascular mortality or
pontaneous MIs during long-term follow-up (2).
rawbacks of the delayed selective invasive strategy. As
ompared with the early invasive strategy, prolonged hos-
italization until PCI (1 day vs. 11 days) and higher rates of
ehospitalization (7.4% vs. 10.9%) initially appeared to be
rawbacks of the delayed selective invasive strategy (3). The
-year ICTUS report (4) clarified that the initial hospital
tays were similar for patients assigned to the 2 strategies (6
ays vs. 7 days, respectively), but these lengths of stay were
otably longer than the hospitalizations in contemporary
rials comparing early versus delayed intervention for ACS
2 days vs. 3 days, p  0.001) (7).
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Comments on the ICTUS Trial March 2, 2010:865–6he timing of an invasive evaluation for NSTEMI. The
esults of ICTUS extend the findings from 2 current studies
7,8) and suggest that the timing of invasive evaluation can
e flexible for most patients with NSTEMI. In many health
are settings, however, concerns about long hospital stays or
he discharge of high-risk patients without an invasive
valuation (8) may limit the broad application of the delayed
elective strategy. Despite the caveats, many strengths of the
CTUS trial have clinical relevance. As a strategy-based
rial, ICTUS allowed physicians caring for patients to adjust
herapy as they might in practice, making the outcome
pplicable to the everyday care of patients with NSTEMI
nd providing reassurance that a selective invasive approach
s an acceptable alternative to an early invasive strategy for
ifferent clinical scenarios. This means, for instance, that
atients with active bleeding and NSTEMI could defer
ngiographic evaluation without incurring additional risk,
nd that low- or moderate-risk patients who stabilize on
edical therapy can be managed conservatively and undergo
emi-elective invasive evaluation should stress testing show
vidence of ischemia.
Regardless of the angiographic strategy ultimately se-
ected for patients with NSTEMI, medical therapy should
nclude the early use of aspirin, a thienopyridine, an anti-
hrombin, beta blockade, statin therapy, intravenous nitro-
lycerin, and probably an angiotensin-converting enzyme
ACE) inhibitor. Platelet-glycoprotein IIb/IIIa inhibitors
ay not be required during initial medical management (9).
he early use of clopidogrel seems appropriate (10) because
8% of patients with ACS require urgent bypass surgery in
ontemporary practice (11).
emaining questions and challenges. The results of the
CTUS trial suggest that patients with NSTEMI who
tabilize on medical therapy can safely wait for an invasive
valuation (2). But the question remains: Is it worth the
ait? In other words, do patients who wait for angiography
ave equally good outcomes and levels of satisfaction as
hose managed with upfront angiography?
Until further research is completed, a dualistic approach
ill dominate the management of ACS. All patients with
STEMI will require intensive medical therapy, and almost
ll patients will undergo invasive procedures. Angiographic
pproaches will prevail because the “plumbing model” of
oronary artery disease comes up in bedside discussions of
CS more often than the new paradigm of endothelial
ysfunction, arterial inflammation, and plaque rupture (12).
n the new era of comparative effectiveness research, how-
ver, cost and quality metrics will be measured alongside
ard clinical outcomes to ultimately define how various
K
itrategies reduce resource utilization and achieve optimal
enefits for patients with NSTEMI.
eprint requests and correspondence: Dr. John A. Bittl, 1221
E 5th Street, Ocala, Florida 34471. E-mail: jabittl@mac.com.
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